drugset
drugset / Trial / NCT01852682

A Phase III Study of PA21 in Peritoneal Dialysis Patients With Hyperphosphatemia

NCT01852682 ↗

Phase 3 Completed Kissei Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate efficacy and safety, when administering PA21, in peritoneal dialysis patients having hyperphosphatemia.

Timeline

Start
—
Primary completion
2014-03
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject PA21 Unknown — —

Indications

hyperphosphatemia